Gogas, Helen <br/><br/>
Prognostic significance of autoimmunity during treatment of melanoma with interferon.  [electronic resource] 

 -  The New England journal of medicine  Feb 2006 
 - 709-18 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa053007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--therapeutic use<br/>Adult<br/>Aged<br/>Analysis of Variance<br/>Autoantibodies--blood<br/>Autoimmunity<br/>Chemotherapy, Adjuvant<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Proportional Hazards Models<br/>Recombinant Proteins<br/>Recurrence<br/>Skin Neoplasms--drug therapy<br/>Survival Analysis